Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
@article{TLCR95505, author = {Mylène Wespiser and Aurélie Swalduz and Maurice Pérol}, title = {Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage}, journal = {Translational Lung Cancer Research}, volume = {14}, number = {1}, year = {2025}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/95505} }